[go: up one dir, main page]

WO2024145451A3 - Methods for restoring regenerative potential of aged lung alveoli and aged adult stem cell compartments - Google Patents

Methods for restoring regenerative potential of aged lung alveoli and aged adult stem cell compartments Download PDF

Info

Publication number
WO2024145451A3
WO2024145451A3 PCT/US2023/086195 US2023086195W WO2024145451A3 WO 2024145451 A3 WO2024145451 A3 WO 2024145451A3 US 2023086195 W US2023086195 W US 2023086195W WO 2024145451 A3 WO2024145451 A3 WO 2024145451A3
Authority
WO
WIPO (PCT)
Prior art keywords
aged
methods
stem cell
adult stem
cell compartments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/086195
Other languages
French (fr)
Other versions
WO2024145451A2 (en
Inventor
Tuomas Tammela
Xueqian ZHUANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of WO2024145451A2 publication Critical patent/WO2024145451A2/en
Publication of WO2024145451A3 publication Critical patent/WO2024145451A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present disclosure provides methods for restoring the regenerative potential of aged lung alveoli or aged adult stem cell compartments in a subject in need thereof comprising administering to the subject an effective amount of an inhibitor of NUPR1/LCN2-2 axis or iron/transferrin. In some embodiments, the subject is diagnosed with or suffers from a lung insufficiency such as COPD, COVID, influenza, and pneumonia sequelae. Also disclosed herein are methods for preventing or treating lung cancer in young (non-aged) subjects comprising administering an inhibitor of NUPR1/LCN2-2 axis, and/or ferroptosis inducing agent.
PCT/US2023/086195 2022-12-29 2023-12-28 Methods for restoring regenerative potential of aged lung alveoli and aged adult stem cell compartments Ceased WO2024145451A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263435914P 2022-12-29 2022-12-29
US63/435,914 2022-12-29

Publications (2)

Publication Number Publication Date
WO2024145451A2 WO2024145451A2 (en) 2024-07-04
WO2024145451A3 true WO2024145451A3 (en) 2024-07-25

Family

ID=91719248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/086195 Ceased WO2024145451A2 (en) 2022-12-29 2023-12-28 Methods for restoring regenerative potential of aged lung alveoli and aged adult stem cell compartments

Country Status (1)

Country Link
WO (1) WO2024145451A2 (en)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090305963A1 (en) * 2005-01-19 2009-12-10 Sukhatme Vikas P Lipocalin 2 for the Treatment, Prevention, and Management of Cancer Metastasis, Angiogenesis, and Fibrosis
US20140294994A1 (en) * 2011-10-28 2014-10-02 Ch-Ying Huang Pharmaceutical composition for elimination of cancer stem cells
US20150164838A1 (en) * 2012-07-19 2015-06-18 Sbi Pharmaceuticals Co., Ltd. Prophylactic/therapeutic agent for influenza virus infection
US20190054115A1 (en) * 2016-03-15 2019-02-21 Solvotrin Therapeutics Ltd Compositions and methods for increasing iron intake in a mammal
US20190192672A1 (en) * 2013-04-09 2019-06-27 Massachusetts Institute Of Technology Drug delivery polymer and uses thereof
US20200306293A1 (en) * 2016-03-31 2020-10-01 United Kingdom Research And Innovation Ferric maltol compositions for use in the treatment or prevention of cancer and tumours
WO2021105384A1 (en) * 2019-11-27 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Targeting the nls region of nupr1 protein to treat cancer
US20210293827A1 (en) * 2020-03-21 2021-09-23 Henry Winchester Methods of diagnosing risk of serious symptoms from covid-19 infection
EP3892275A1 (en) * 2020-04-08 2021-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosolization of hcq or its metabolites for the treatment of lung infections
WO2021222660A1 (en) * 2020-04-30 2021-11-04 Kaleido Biosciences, Inc. Oligosaccharide compositions and methods of use thereof for treating viral infections
WO2021242751A1 (en) * 2020-05-28 2021-12-02 Hu Mickey Compositions and methods for treating sars-cov-2
US20220275055A1 (en) * 2019-05-30 2022-09-01 National Institute Of Biological Sciences, Beijing Drug target of idiopathic pulmonary fibrosis

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090305963A1 (en) * 2005-01-19 2009-12-10 Sukhatme Vikas P Lipocalin 2 for the Treatment, Prevention, and Management of Cancer Metastasis, Angiogenesis, and Fibrosis
US20140294994A1 (en) * 2011-10-28 2014-10-02 Ch-Ying Huang Pharmaceutical composition for elimination of cancer stem cells
US20150164838A1 (en) * 2012-07-19 2015-06-18 Sbi Pharmaceuticals Co., Ltd. Prophylactic/therapeutic agent for influenza virus infection
US20190192672A1 (en) * 2013-04-09 2019-06-27 Massachusetts Institute Of Technology Drug delivery polymer and uses thereof
US20190054115A1 (en) * 2016-03-15 2019-02-21 Solvotrin Therapeutics Ltd Compositions and methods for increasing iron intake in a mammal
US20200306293A1 (en) * 2016-03-31 2020-10-01 United Kingdom Research And Innovation Ferric maltol compositions for use in the treatment or prevention of cancer and tumours
US20220275055A1 (en) * 2019-05-30 2022-09-01 National Institute Of Biological Sciences, Beijing Drug target of idiopathic pulmonary fibrosis
WO2021105384A1 (en) * 2019-11-27 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Targeting the nls region of nupr1 protein to treat cancer
US20210293827A1 (en) * 2020-03-21 2021-09-23 Henry Winchester Methods of diagnosing risk of serious symptoms from covid-19 infection
EP3892275A1 (en) * 2020-04-08 2021-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosolization of hcq or its metabolites for the treatment of lung infections
WO2021222660A1 (en) * 2020-04-30 2021-11-04 Kaleido Biosciences, Inc. Oligosaccharide compositions and methods of use thereof for treating viral infections
WO2021242751A1 (en) * 2020-05-28 2021-12-02 Hu Mickey Compositions and methods for treating sars-cov-2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHULTZ MICHAEL B., SINCLAIR DAVID A.: "When stem cells grow old: phenotypes and mechanisms of stem cell aging", DEVELOPMENT, THE COMPANY OF BIOLOGISTS LTD., GB, vol. 143, no. 1, 1 January 2016 (2016-01-01), GB , pages 3 - 14, XP093197752, ISSN: 0950-1991, DOI: 10.1242/dev.130633 *

Also Published As

Publication number Publication date
WO2024145451A2 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
Baker et al. Impaired pulmonary vascular development in bronchopulmonary dysplasia
Maffey et al. Viruses and atypical bacteria associated with asthma exacerbations in hospitalized children
ES2629502T3 (en) Methods and compositions related to mesenchymal stem cell exosomes
Moskwa et al. Innate immune response to viral infections in primary bronchial epithelial cells is modified by the atopic status of asthmatic patients
Rao et al. Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen
Greenough et al. Perinatal prevention of bronchopulmonary dysplasia.
WO2020247675A1 (en) Methods for attenuating viral infection and for treating lung injury
Alanazi et al. Post-transplant cyclophosphamide combined with anti-thymocyte globulin as graft-versus-host disease prophylaxis for allogeneic hematopoietic cell transplantation in high-risk acute myeloid leukemia and myelodysplastic syndrome
EP4548975A3 (en) Nitric oxide inhalation therapy for infants with bronchiolitis
WO2024145451A3 (en) Methods for restoring regenerative potential of aged lung alveoli and aged adult stem cell compartments
Lin et al. Cytomegalovirus infection and treatment in allogeneic hematopoietic stem cell transplantation: a retrospective study from a single institution in an endemic area
Krasowska-Kwiecien et al. Mesenchymal stem cells as a salvage treatment for severe refractory graft-vs-host disease in children after bone marrow transplantation
Iguchi et al. Graft‐versus‐host disease (GVHD) prophylaxis by using methotrexate decreases pre‐engraftment syndrome and severe acute GVHD, and accelerates engraftment after cord blood transplantation
Wu et al. Prospective study of a modified post-transplantation cyclophosphamide regimen for severe aplastic anemia patients with HLA-haploidentical transplantation
Pipkorn Budesonide and nasal histamine challenge
Potapova et al. Apoptotic endothelial cells demonstrate increased adhesiveness for human mesenchymal stem cells
Yepes Neurological complications of SARS-CoV-2 Infection and COVID-19 vaccines: from molecular mechanisms to clinical manifestations
Fox Congenital aural fistula
Huang et al. Complications and death causes of peripheral blood stem cell transplantation in the treatment of thalassemia major
Aytaç et al. Dynamics in children and adolescents who experience varicella zoster virus infections after haematopoietic stem cell transplantation: a case-control study
Januškevičiūtė et al. What we learned about headache during the COVID-19 pandemic: literature review
Gien et al. Persistent Pulmonary Hypertension of the Newborn
HONG et al. Allogeneic hematopoietic stem cell transplantation for β-thalassemia major patients using a reduced-intensity conditioning regimen
Talha et al. Evaluating the Respiratory Support Pattern and Relationship with Initial Oxygen Saturation of the COVID Isolation Unit Patients in Sylhet
CN115381843A (en) Use of L-fucose in the preparation of drugs for treating respiratory diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23913717

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE